SOPHIA ANTIPOLIS, France – January 20, 2025 │ The therapeutic RNA landscape continues to evolve with a robust pace of innovation. The latest Q4 2024 edition of our Therapeutic mRNA patent monitor highlights significant developments in intellectual property activities, shedding light on key contributors and trends in this dynamic field.
Key Highlights from Q4 2024
The total number of new patent publications in the therapeutic mRNA sector has continued to grow, reflecting the field’s dynamic expansion and sustained momentum. This consistent upward trend underscores the industry’s efforts to meet the growing demand for RNA-based therapies and vaccines, see the figure 1.
BioNTech and Moderna remain at the forefront of mRNA-related patent filings, reaffirming their leadership with several new patent families published during the quarter. While these numbers represent a slight decline compared to the same period last year, their ongoing efforts underscore their commitment to driving innovation in the sector.
A noteworthy development this quarter is Yale University’s rise to prominence in the mRNA patent landscape. Claiming the third position in terms of new patent publications, Yale was absent from the top ten during the same quarter last year. This remarkable leap highlights an investment in mRNA innovation that warrants close monitoring as academic research continues to play pivotal role in shaping the future of the field.
Figure 1: Q4 2023 vs Q4 2024 regarding new patent applications
New granted patents also made headlines in Q4 2024. Moderna strengthened its intellectual property portfolio with several new patents, while BioNTech followed closely behind. A considerable portion of these newly enforced rights originated from Asian assignees, emphasizing the increasingly globalized nature of mRNA technological advancements.
This sustained innovation in the therapeutic RNA field is a testament to the sector’s resilience and the pivotal role of intellectual property in fostering groundbreaking advancements. The insights from this monitor reveal how key players and institutions are shaping the future of RNA-based technologies and treatments.
Why subscribe to this monitor?
A patent monitor is an essential resource for businesses striving to remain competitive in advanced fields like mRNA therapeutics. Our tailored monitoring services provide timely and curated insights into patent activities, helping organizations stay abreast of technological advancements, identify collaboration opportunities, and protect their innovations from infringement. By leveraging our bespoke IP intelligence solutions, companies gain the strategic insights needed to make informed decisions, effectively navigate the complexities of intellectual property, and foster growth and innovation within their industries.
For more detailed insights into these developments and how they may impact your business, please contact us.